These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24727325)

  • 21. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
    Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
    Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
    Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
    Ng K; Ogino S; Meyerhardt JA; Chan JA; Chan AT; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Benson AB; Schaefer PL; Whittom R; Hantel A; Goldberg RM; Bertagnolli MM; Venook AP; Fuchs CS
    J Natl Cancer Inst; 2011 Oct; 103(20):1540-51. PubMed ID: 21849660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between
    Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
    J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.
    Ryan BM; Robles AI; Harris CC
    Clin Cancer Res; 2012 Jun; 18(12):3487-8; author reply 3489. PubMed ID: 22669132
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
    Gonsalves WI; Mahoney MR; Sargent DJ; Nelson GD; Alberts SR; Sinicrope FA; Goldberg RM; Limburg PJ; Thibodeau SN; Grothey A; Hubbard JM; Chan E; Nair S; Berenberg JL; McWilliams RR;
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
    Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
    Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.
    Marinović S; Škrtić A; Catela Ivković T; Poljak M; Kapitanović S
    Hum Cell; 2021 Sep; 34(5):1455-1465. PubMed ID: 34235620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
    Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
    Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
    Kazmi HR; Chandra A; Kumar S; Satyam LK; Gupta A; Nigam J; Srivastava M; Mittal B
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2577-2583. PubMed ID: 27620744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
    Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
    Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
    Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M
    Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.